Updated:
Iterum Therapeutics plc
Iterum Therapeutics plc was founded as a clinical-stage biopharmaceutical company, building on research into penem-class antibiotics. CEO Corey N.
Iterum Therapeutics plc
Iterum Therapeutics plc was founded as a clinical-stage biopharmaceutical company, building on research into penem-class antibiotics. CEO Corey N. Fishman has been at the helm since inception, steering the development of sulopenem, an oral and intravenous antibiotic candidate. The company emerged from its predecessor, Spero Therapeutics, focusing on the challenge of beta-lactamase resistance. The firm concentrates on a single therapeutic area: infectious disease, specifically gram-negative bacteria. Iterum has conducted multiple Phase 3 trials for sulopenem in complicated urinary tract infections and intra-abdominal infections (per ClinicalTrials.gov). The company does not disclose investment from external family offices or institutional allocators as a sponsor. Iterum trades on the Nasdaq under the ticker ITRM, with market capitalization fluctuating around $50 million as of late 2025 (per Nasdaq data). The small market cap reflects its pre-commercial status and reliance on regulatory approval. Fishman's prior roles include executive positions at Paratek Pharmaceuticals and Cubist Pharmaceuticals. A structural differentiator is Iterum's public-company structure, making it transparent to SEC reporting rather than a private family office. It funds R&D through public equity raises and potential partnerships, distinct from a privately-held venture model. The firm's narrow pipeline—one drug, one mechanism—creates a binary risk profile absent in diversified biotech firms.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Ireland
City
Dublin
Corporate office
Fitzwilliam Court, Leeson Close, Dublin 2, Ireland
Principals
Corey N. Fishman
Chief Executive Officer
Sector focus
Frequently asked questions
Who makes investment decisions at Iterum Therapeutics?
Investment decisions at Iterum Therapeutics are made by CEO Corey N. Fishman and the board, guided by corporate strategy and clinical trial results. The company is publicly traded, so capital allocation is subject to shareholder approval as outlined in SEC filings (per SEC filings).
What is Iterum's core pipeline focus?
Iterum's pipeline is centered on sulopenem, a penem-class antibiotic designed to treat infections caused by multidrug-resistant gram-negative bacteria. The company has focused on oral and intravenous formulations, with Phase 3 trials in complicated urinary tract infections and intra-abdominal infections.
How is Iterum Therapeutics funded?
Iterum is funded through public equity offerings, including follow-on offerings and at-the-market programs, as a Nasdaq-listed company (per SEC filings). It also accesses government grants and has not disclosed substantial family office or direct institutional capital beyond common stock.
Is Iterum Therapeutics related to a family office?
No, Iterum Therapeutics is not a family office or managed by one. It is a publicly traded biopharmaceutical company with no disclosed family-office ownership structure.
What regulatory milestones has Iterum achieved?
Iterum has reported positive Phase 3 results for oral sulopenem in uncomplicated urinary tract infections in October 2024. As of early 2025, it has not yet received FDA approval for any drug candidate (per company press releases).
What is the geographical focus of Iterum's operations?
Iterum is headquartered in Dublin, Ireland, with clinical operations primarily in the United States and Europe. Clinical trials have enrolled patients across multiple sites in North America and Europe (per ClinicalTrials.gov).
How does Iterum differ from other biotech firms?
Iterum's narrow focus on a single antibiotic drug class (sulopenem) and its public-company structure distinguish it from diversified biotechs. It lacks a broad pipeline, concentrating on one late-stage asset, creating high binary risk.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: